SMARCA4 Mutation clinical trials at University of California Health
1 in progress, 0 open to eligible people
Showing trials for
PRT7732, an Oral SMARCA2 Degrader, in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation
Sorry, not currently recruiting here
This is a Phase 1 study to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of PRT7732 in patients with select advanced or metastatic solid tumors with a SMARCA4 mutation.
at UCSF
Last updated: